Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Kate Hunter

Associate

Nashville
(615) 742-7822 TEL
(615) 742-0475 FAX

Kate Hunter

Associate

Nashville
(615) 742-7822 TEL
(615) 742-0475 FAX
Nashville
(615) 742-7822 TEL
(615) 742-0475 FAX

Kate Hunter concentrates her practice on investigations and litigation related to inquiries involving alleged violations of the False Claims Act (FCA), the Foreign Corrupt Practices Act (FCPA), various securities laws and other federal statutes. She represents healthcare companies in responding to government investigations concerning issues of alleged healthcare fraud and abuse. She regularly counsels clients on compliance with the FCA and defends clients related to various state and federal agency investigations. 

In addition, Kate helps clients stay up-to-date on regulatory developments related to corporate compliance matters and assists clients in conducting internal investigations and preparing and implementing anti-corruption compliance programs.

Prior to joining Bass, Berry & Sims, Kate was an associate in the Washington, D.C. office of Norton Rose Fulbright. Kate earned her law degree and an LL.M. in international and comparative law from Duke University School of Law. She earned a B.A. in international relations and economics from Tufts University.

News

View More

Publications

View More

Additional Thought Leadership

Publications:

  • "Hoskins – A Limit on the U.S. Long-arm Reach over Corruption" (co-author), Fraud Intelligence (October 2015)
  • "The Dodd-Frank Act Whistleblower Provisions and the SEC Whistleblower Program in 2014" (co-author), State Bar of Texas Corporate Counsel Section Newsletter (Winter 2015)
  • "Deferred Prosecution and Non-prosecution Agreements in the United States, England, and Wales" (co-author), The Review of Securities & Commodities Regulation (February 4, 2015)

Accolades

Phi Beta Kappa

Duke Journal of Comparative & International Law – Editor-in-Chief

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.